Urinary Incontinence Episodes per Day

There were seven studies used to compare the efficacy of the three modalities on the number of incontinence episodes per day at 12 weeks follow-up [12,13,15–17,20,22]. Pair-wise comparisons with a RE model revealed that all three modalities were more efficacious than the placebo (Table 2). The NMA demonstrated that SNM was associated with a greater reduction in the total number of incontinence episodes per day compared with the placebo, PTNS, and OnabotulinumtoxinA. There was no significant difference between the efficacy of OnabotulinumtoxinA and PTNS (Table 3). The ranking results for incontinence episode reduction was as follows: SNM ranked first, PTNS ranked second, OnabotulinumtoxinA ranked third, and placebo ranked fourth (Figure 3B).
